Amphastar Pharmaceuticals (AMPH) Competitors $23.88 -0.53 (-2.17%) Closing price 04:00 PM EasternExtended Trading$23.87 -0.01 (-0.04%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMPH vs. ELAN, PCVX, RYTM, PTCT, RNA, ACLX, RARE, ZLAB, AKRO, and MRUSShould you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Elanco Animal Health (ELAN), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Akero Therapeutics (AKRO), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Amphastar Pharmaceuticals vs. Elanco Animal Health Vaxcyte Rhythm Pharmaceuticals PTC Therapeutics Avidity Biosciences Arcellx Ultragenyx Pharmaceutical Zai Lab Akero Therapeutics Merus Amphastar Pharmaceuticals (NASDAQ:AMPH) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Which has more volatility & risk, AMPH or ELAN? Amphastar Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Does the media prefer AMPH or ELAN? In the previous week, Elanco Animal Health had 15 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 20 mentions for Elanco Animal Health and 5 mentions for Amphastar Pharmaceuticals. Amphastar Pharmaceuticals' average media sentiment score of 1.31 beat Elanco Animal Health's score of 0.83 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 17 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AMPH or ELAN more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Elanco Animal Health's net margin of 4.60%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Elanco Animal Health's return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Elanco Animal Health 4.60%6.78%3.03% Which has better earnings & valuation, AMPH or ELAN? Amphastar Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$731.97M1.57$137.54M$3.067.91Elanco Animal Health$4.44B1.07-$1.23B$0.6714.22 Do analysts rate AMPH or ELAN? Amphastar Pharmaceuticals currently has a consensus price target of $43.50, suggesting a potential upside of 79.71%. Elanco Animal Health has a consensus price target of $14.67, suggesting a potential upside of 53.90%. Given Amphastar Pharmaceuticals' higher possible upside, research analysts clearly believe Amphastar Pharmaceuticals is more favorable than Elanco Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Elanco Animal Health 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.43 Does the MarketBeat Community favor AMPH or ELAN? Amphastar Pharmaceuticals received 250 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 65.88% of users gave Amphastar Pharmaceuticals an outperform vote while only 54.62% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39265.88% Underperform Votes20334.12% Elanco Animal HealthOutperform Votes14254.62% Underperform Votes11845.38% Do institutionals and insiders hold more shares of AMPH or ELAN? 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAmphastar Pharmaceuticals beats Elanco Animal Health on 11 of the 18 factors compared between the two stocks. Get Amphastar Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMPH vs. The Competition Export to ExcelMetricAmphastar PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.15B$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio8.077.3222.5518.49Price / Sales1.57239.19394.97102.66Price / Cash7.1765.8538.1834.62Price / Book1.816.436.694.25Net Income$137.54M$143.21M$3.22B$248.31M7 Day Performance0.56%1.24%1.11%1.12%1 Month Performance-14.44%6.09%3.59%3.68%1 Year Performance-42.48%-3.34%15.65%5.19% Amphastar Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMPHAmphastar Pharmaceuticals4.505 of 5 stars$23.88-2.2%$43.50+82.2%-40.8%$1.13B$731.97M7.961,620Upcoming EarningsPositive NewsELANElanco Animal Health3.9447 of 5 stars$8.48+0.5%$14.67+73.0%-28.0%$4.21B$4.44B21.209,800Upcoming EarningsShort Interest ↑PCVXVaxcyte3.0357 of 5 stars$30.39-0.8%$136.50+349.2%-40.8%$3.91BN/A-6.61160Upcoming EarningsPositive NewsRYTMRhythm Pharmaceuticals3.7061 of 5 stars$60.48-2.0%$74.92+23.9%+64.0%$3.82B$130.13M-13.97140Upcoming EarningsPositive NewsPTCTPTC Therapeutics4.0723 of 5 stars$48.19+1.7%$63.77+32.3%+55.0%$3.80B$806.78M-8.111,410Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsRNAAvidity Biosciences2.8518 of 5 stars$28.52+7.0%$66.69+133.8%+35.3%$3.43B$10.90M-9.90190Upcoming EarningsPositive NewsACLXArcellx1.8296 of 5 stars$60.93-1.8%$110.67+81.6%+29.8%$3.35B$107.94M-85.8280Upcoming EarningsNews CoveragePositive NewsRAREUltragenyx Pharmaceutical4.3496 of 5 stars$35.40-0.8%$92.79+162.1%-8.4%$3.32B$560.23M-5.581,310Upcoming EarningsShort Interest ↑Positive NewsZLABZai Lab2.1548 of 5 stars$29.71+3.0%$47.37+59.4%+100.6%$3.26B$398.99M-10.731,950Upcoming EarningsAKROAkero Therapeutics3.7973 of 5 stars$37.67+0.1%$76.29+102.5%+129.3%$3.00BN/A-10.0530Insider TradeNews CoveragePositive NewsMRUSMerus3.4307 of 5 stars$43.23+0.4%$85.31+97.3%+1.3%$2.99B$36.13M-10.9437Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies ELAN Competitors PCVX Competitors RYTM Competitors PTCT Competitors RNA Competitors ACLX Competitors RARE Competitors ZLAB Competitors AKRO Competitors MRUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMPH) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMPH Stock Free AMPH Stock Alerts